Message #18 From:
NewsBot Date: October 11, 2006 08:53:00 AM
EGEI News eGene Inc. Will Introduce the First Automated HLA SSP Genotyping System at the 2006 Annual Meeting of the American Society for Histocompatibility and Immunogenetics in San Diego, California, October 16-20, 2006
IRVINE, Calif.--(BUSINESS WIRE)--eGene Inc. (OTCBB:EGEI),
developer of a revolutionary high-performance genetic analysis
technology, today announced that it will introduce the first automated
HLA SSP genotyping system at the 32nd annual meeting of The
American Society for Histocompatibility and Immunogenetics (ASHI) at the
Sheraton San Diego Hotel & Marina in San Diego, California, on October
16-20, 2006.
Ming S. Liu, CEO of eGene, made the announcement noting: "eGene’s
HLA SSP digital genotyping technology will benefit HLA (human
leukocyte antigen) genotyping analysis by not only replacing
labor-intensive slab gel electrophoresis methods but also simplifying
and digitalizing the tedious data process work. eGene will attend this
meeting to introduce our products to HLA laboratories. We will host a
customer presentation and live system demonstrations during this
meeting, so people can experience first-hand our automated genotyping
technology. Our automated HDA-GT12 genetic analyzer has already been
used by HLA lab in the City of Hope Hospital National Medical Center for
more than 30,000 tests per month. There are nearly 600 HLA laboratories
worldwide routinely checking the individual HLA genotype for organ and
bone marrow transplantation. We believe our automatic, affordable,
user-friendly genotyping system represents the future of HLA genotyping
analysis."
eGene's Booth Number is 512.
About ASHI
ASHI (www.ashi-hla.org) is a
not-for-profit association of clinical and research professionals
including immunologists, geneticists, molecular biologists, transplant
physicians and surgeons, pathologists and technologists. As a
professional society involved in histocompatibility, immunogenetics and
transplantation, ASHI is dedicated to advancing the science and
application of histocompatibility and immunogenetics; providing a forum
for the exchange of information; and advocating the highest standards of
laboratory testing in the interest of optimal patient care.
ASHI is a member of the United Network for Organ Sharing and has
liaisons with several other scientific and medical organizations
including the College of American Pathologists, American Association of
Blood Banks, American Association of Tissue Banks, American Society of
Human Genetics, the National Marrow Donor Program, American Board of
Transplant Coordinators, North American Transplant Coordinators
Organization, American Society of Transplant Physicians, American
Society of Transplant Surgeons, and the American Board of
Histocompatibility and Immunogenetics.
About eGene Inc.
eGene Inc. (www.egeneinc.com)
focuses its core technologies of capillary electrophoresis,
microfluidics, liquid handling and automation to develop and manufacture
low-cost microfluidic, miniaturized digital genetic analyzer systems,
software and consumables for biological materials testing applications.
These products detect, quantify, identify and characterize DNA and RNA
at high rates of specificity and sensitivity while automating routine
and non-routine laboratory and industrial procedures critical to product
safety, development quality and productivity.
eGene’s HDA-GT12(TM) Genetic Analyzer is in
use at more than 100 hospitals and research centers worldwide. The
system analyzes genetic fingerprinting of living organisms through
microsatellites, AFLP and RFLP. It performs fast DNA sample screening
and high-resolution DNA fragment analysis (2-5bp). The system also
analyzes the quality and quantity of total RNA and cRNA, determines the
efficiency of cRNA and cDNA amplification reactions and ensures quality
of fragmented cRNA. The company sells cartridges that are specific to
the type of analysis to be performed. All data is then received in
digital form for appropriate transmission and storage.
This press release contains forward-looking statements within the
meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995. Such
statements are made based on management's current expectations and
beliefs. Actual results may vary from those currently anticipated based
upon a number of factors. The Company undertakes no obligation to
release publicly any revision, which may be made to reflect events or
circumstances after the date hereof.
